Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Amarin, Ester Neurosciences Ltd. deal

AMRN will acquire Ester for $5 million in cash and

Read the full 109 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE